In Depth Research on Cancer Targeted Therapy Market & Clinical Insight 2015

“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:

* Introduction & Categorization of Cancer Targeted Therapies
* Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
* Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
* Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
* Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
* Global Cancer Targeted Therapeutics Market Dynamics
* Future Prospects of Cancer Targeted Therapies

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Cancer-Targeted-Therapy-Market-&-Clinical-Insight-2015.php

Table of Contents

1. Introduction to Cancer Targeted Therapeutics

2. Need for Cancer Targeted Therapeutics

3. Categorization of Cancer Targeted Therapies

4. Consideration of Cancer Vaccines as Targeted Therapeutics

5. Mechanism of Cancer Vaccines
5.1 Idiotype Cancer Vaccine Mechanism
5.2 Cellular Cancer Vaccines Mechanism
5.3 Ganglioside Antigens based Cancer Vaccines Mechanism
5.4 Peptide Cancer Vaccine Mechanism
5.5 Tumor Host Interaction Cancer Vaccine Mechanism

6. Mechanisms of Cancer Targeted Monoclonal Antibodies
6.1 Tumor Antigens as Targets of Antibodies
6.2 Development of Antibodies for Clinical Purposes
6.3 Complement Dependent Cytotoxicity (CDC)
6.4 Signal Transduction Changes

7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics

8. Mechanism of Oncogene Inhibitors

9. Global Cancer Targeted Therapy Market Overview
9.1 Current Market Scenario
9.2 Cancer Targeted Therapy Clinical Pipeline Insight


10. Global Cancer Targeted Therapeutics Market Dynamics
10.1 Favorable Market Parameters
10.2 Commercialization Challenges

11. Future Prospects of Cancer Targeted Therapeutics

12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase I
12.6 Phase I/II
12.7 Phase II
12.8 Phase II/III
12.9 Phase III
12.10 Preregistration
12.11 Registered

13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country

14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered

15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country

16. Oncogene Inhibitors Pipeline by Company, Indication & Phase
16.1 Oncogene Protein Inhibitors Pipeline
16.2 Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline
16.3 Proto Oncogene Protein b raf Inhibitors Pipeline
16.4 Proto Oncogene Protein c-kit Inhibitors Pipeline
16.5 Proto-Oncogene Protein c-rel Inhibitors Pipeline
16.6 Proto Oncogene Protein c-akt Inhibitors Pipeline
16.7 Proto Oncogene Protein c met Inhibitors Pipeline
16.8 Proto Oncogene Protein c ret Inhibitors Pipeline
16.9 Proto-Oncogene Protein c mdm2 Inhibitors Pipeline
16.10 Proto-Oncogene Protein Inhibitors Pipeline
16.11 Proto-Oncogene-Protein-c-ets Inhibitors Pipeline
16.12 Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline
16.13 Proto Oncogene Proteins c pim 1 Inhibitors Pipeline
16.14 Proto Oncogene Protein c-myc Inhibitors Pipeline
16.15 Multiple Oncogene Inhibitors Pipeline

17. Marketed Oncogene Inhibitors by Company & Indication

18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase
18.1 Unknown
18.2 Research
18.3 Preclinical
18.4 Clinical
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-II/III
18.9 Phase-III
18.10 Preregistration
18.11 Registered

19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors

20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication
20.1 Unknown
20.2 Research
20.3 Preclinical
20.4 Clinical
20.5 Phase-I
20.6 Phase-I/II
20.7 Phase-II
20.8 Phase-III

21. Marketed Cancer Targeted Angiogenesis Inhibitors

22. Competitive Landscape
22.1 Advaxis
22.2 Bind Therapeutics
22.3 Boehringer Ingelheim
22.4 Bristol Mayer Squibb
22.5 Celldex Therapeutics
22.6 Dendreon Corporation
22.7 Eli Lily
22.8 GalaxoSmithKline
22.9 Galena Biopharma
22.10 Genetech
22.11 ImmunoCellular Therapeutics
22.12 ImmunoGen
22.13 Inovio Pharmaceuticals
22.14 Johnson & Johnson
22.15 NeoStem Oncology
22.16 NewLink Genetics
22.17 Northwest Biotherapeutics
22.18 Merck
22.19 Novartis
22.20 Peregrine Pharmaceuticals
22.21 Pfizer
22.22 Roche
22.23 Sanofi
22.24 Seattle Genetics
22.25 Teva

Figure 1-1: Uses of Pharmacogenomics
Figure 1-2: Developmental Stages of Targeted Therapeutics
Figure 1-3: Cancer Target Identification Techniques
Figure 1-4: Genetic Anomalies Classification
Figure 1-5: Mechanism of Cancer Targeted Therapeutics
Figure 1-6:Improvements Required for Cancer Targeted Therapies
Figure 2-1: Objectives of Cancer Targeted Therapeutics
Figure 2-2: Benefits of Cancer Targeted Therapeutics
Figure 3-1: Categorization of Cancer Targeted Therapeutics on the Basis of Molecular Size
Figure 3-2: Features of Cancer Targeted Small Molecules Drugs
Figure 3-3: Features of Cancer Targeting Antibodies
Figure 3-4: Classification of Cancer Targeted Therapies on the Basis of their Mechanism
Figure 4-1: Classification of Cancer Vaccines
Figure 4 2: Distinction of Cancer Vaccines
Figure 5-1: Classification of Different Types of Cancer vaccines
Figure 7-1: Benefits of Cancer Tyrosine Kinase Targeted Therapeutics
Figure 7-2: Classification of Tyrosine Kinase
Figure 7-3: Mechanism of Cancer Tyrosine Kinase Targeted Therapeutics
Figure 7-4: Mechanism of VEGFR
Figure 8-1: Activation of Proto-Oncogenes to Oncogenes
Figure 8-2:Benefits of Oncogene Inhibitors
Figure 8-3: Mechanism of Crizotinib
Figure 8-4: Mechanism of Vemurafenib
Figure 8-5: Mechanism of Vorinostat
Figure 9-1: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (%), 2015
Figure 9-2: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (Number), 2015
Figure 9-3: Global Cancer Vaccines Clinical Pipeline by Phase (%), 2015
Figure 9-4: Global Cancer Vaccines Clinical Pipeline by Phase (Number), 2015
Figure 9-5: Cancer Tyrosine Kinase Inhibitors Pipeline by Phase (%), 2015
Figure 9-6: Cancer Tyrosine Kinase Inhibitors Pipeline by Phase (Number), 2015
Figure 9-7: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
Figure 9-8: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
Figure 9-9: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015
Figure 9-10: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015
Figure 9-11: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
Figure 9-12: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
Figure 9-13: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
Figure 9-14: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
Figure 9-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
Figure 9-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
Figure 9-17: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015
Figure 9-18: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015
Figure 9-19: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
Figure 9-20: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
Figure 9-21: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015
Figure 9-22: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015
Figure 9-23: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015
Figure 9-24: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015
Figure 9-25: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
Figure 9-26: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015
Figure 9-27: Angienesis Inhibitors Pipeline by Phase (%), 2015
Figure 22-1: Advaxis Clinical Pipeline
Figure 22-2: Celldex Therapeutics Clinical Pipeline
Figure 22-3: Galena Biopharma Clinical Pipeline
Figure 22-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 22-5: ImmunoGen Clinical Pipeline
Figure 22-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 22-7: NewLink Genetics Corporation Clinical Pipeline
Figure 22-8: Northwest Biotherapeutics Clinical Pipeline
Figure 22-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 22-10: Seattle Genetics Clinical Pipeline

Table 2-1: Difference between Chemotherapeutics & Targeted Therapeutics
Table 3-1: Suffix used for Targeted Therapeutics
Table 3-2: Naming of Small Molecule Targeted Therapeutics
Table 3-3: Nomenclature of Monoclonal Antibodies
Table 9-1: Breast Cancer Targeted Therapeutics
Table 9-2: Lung Cancer Targeted Therapeutics

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.